长期治疗特泽帕提德的高风险患者的严重小肠阻塞:一个病例报告
Shamsun Nahar1,2, Nelly Maybee3, Nowrin Tamanna4,5
1Internal Medicine, Augusta Health, Fishersville, USA.
Cureus
|January 12, 2026
概括
蒂尔泽帕提德是一种糖尿病和肥胖症药物,可在易感患者中引起严重便秘和肠道阻塞. 对服用这种药物的人来说,密切监测肠道功能至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,有效治疗2型糖尿病 (T2DM) 和肥胖.
- 它的机制包括增强胰岛素敏感性和减缓胃排空.
- 胃肠道 (GI) 的副作用,包括改变运动能力,是众所周知的问题.
研究的目的:
- 报告一例罕见的严重小肠阻塞病例,该病例发生在接受提尔泽帕提德治疗的患者身上.
- 探索特泽帕提德诱导的胃肠道运动变化在阻塞性并发症中的潜在贡献作用.
主要方法:
- 一个61岁的女性患有T2DM和长期治疗tirezepatide的病态肥胖症的病例报告.
- 详细介绍了临床表现,诊断成像 (CT扫描) 和手术干预 ( laparoscopic 粘结溶解转换为腹腔切除术).
- 进行了切除肠道的病理检查.
主要成果:
- 患者出现了渐进的便秘,随后出现了严重的小肠阻塞,需要手术切除死肠.
- 提尔泽帕提德治疗导致HbA1c,体重和肝功能显著改善.
- 在手术期间的发现显示了粘合性疾病和内部作为直接原因,但发现了与tirezepatide的时间联系.
结论:
- 虽然粘合性疾病导致了阻塞,但蒂尔泽帕提德诱导的肠道机动性变化可能有助于导致便秘恶化.
- 这一案例突出显示了在提尔泽帕提德治疗的预易性患者中,阻塞性胃肠道并发症的潜在风险.
- 临床医生应密切监测肠道功能,并考虑在使用蒂尔泽帕提德的患者中进行阻塞性症状的成像.
相关概念视频
01:21Inflammatory Bowel Disease V: Surgical Management
433
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
433
01:21Drugs for Treatment of Constipation-Predominant IBS
688
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
688
01:17Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615
01:29Drugs for Treatment of Ulcerative Colitis in IBD
448
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
448